Epigenetic modification is linked to Alzheimer's disease: is it a maker or a marker?

BMB Rep. 2010 Oct;43(10):649-55. doi: 10.5483/BMBRep.2010.43.10.649.

Abstract

Alzheimer's disease (AD) is the most common age-dependent neurodegenerative disorder and shows progressive memory loss and cognitive decline. Intraneuronal filaments composed of aggregated hyperphosphorylated tau protein, called neurofibrillary tangles, along with extracellular accumulations of amyloid ß protein (Aß), called senile plaques, are known to be the neuropathological hallmarks of AD. In light of recent studies, epigenetic modification has emerged as one of the pathogenic mechanisms of AD. Epigenetic changes encompass an array of molecular modifications to both DNA and chromatin, including transcription factors and cofactors. In this review, we summarize how DNA methylation and changes to DNA chromatin packaging by post-translational histone modification are involved in AD. In addition, we describe the role of SIRTs, histone deacetylases, and the effect of SIRT-modulating drugs on AD. Lastly, we discuss how amyloid precursor protein (APP) intracellular domain (AICD) regulates neuronal transcription. Our understanding of the epigenomes and transcriptomes of AD may warrant future identification of novel biological markers and beneficial therapeutic targets for AD.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alzheimer Disease / genetics*
  • Animals
  • Biomarkers* / analysis
  • Biomarkers* / metabolism
  • Chromatin Assembly and Disassembly / genetics
  • Chromatin Assembly and Disassembly / physiology
  • Epigenesis, Genetic / physiology*
  • Genetic Predisposition to Disease*
  • Humans
  • Models, Biological
  • Sirtuins / metabolism
  • Sirtuins / physiology

Substances

  • Biomarkers
  • Sirtuins